PMVP PMV Pharmaceuticals Inc
Price (delayed)
$1.04
Market cap
$54.01M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.14
Enterprise value
$14.32M
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants. p53 mutations are found in approximately half of all cancers.
Highlights
The debt has dropped by 91% year-on-year and by 91% since the previous quarter
The EPS is up by 21% year-on-year but it has declined by 14% since the previous quarter
The company's net income rose by 15% YoY but it fell by 14% QoQ
PMVP's equity is down by 22% year-on-year and by 11% since the previous quarter
The quick ratio is down by 19% YoY and by 13% QoQ
Key stats
What are the main financial stats of PMVP
Market
Valuations
Earnings
Shares outstanding
51.93M
Market cap
$54.01M
Enterprise value
$14.32M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.31
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$85.45M
Net income
-$58.71M
EBIT
-$74.81M
EBITDA
-$73.91M
Free cash flow
-$51.69M
Per share
Balance sheet
Liquidity
EPS
-$1.14
EPS diluted
-$1.14
Free cash flow per share
-$1
Book value per share
$3.4
Revenue per share
$0
TBVPS
$3.71
Total assets
$191.29M
Total liabilities
$15.21M
Debt
$1.19M
Equity
$176.08M
Working capital
$161.29M
Debt to equity
0.01
Current ratio
12.22
Quick ratio
11.79
Net debt/EBITDA
0.54
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-26.4%
Return on equity
-29.3%
Return on invested capital
-43.4%
Return on capital employed
-42.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PMVP stock price
How has the PMV Pharmaceuticals stock price performed over time
Intraday
-3.7%
1 week
1.96%
1 month
-14.05%
1 year
-39.18%
YTD
-31.13%
QTD
-4.59%
Financial performance
How have PMV Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$85.45M
Net income
-$58.71M
Gross margin
N/A
Net margin
N/A
The company's net income rose by 15% YoY but it fell by 14% QoQ
PMVP's operating income is down by 8% from the previous quarter and by 7% YoY
Growth
What is PMV Pharmaceuticals's growth rate over time
Valuation
What is PMV Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.31
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 21% year-on-year but it has declined by 14% since the previous quarter
PMVP's price to book (P/B) is 87% less than its 5-year quarterly average of 2.4 and 23% less than its last 4 quarters average of 0.4
PMVP's equity is down by 22% year-on-year and by 11% since the previous quarter
Efficiency
How efficient is PMV Pharmaceuticals business performance
PMV Pharmaceuticals's ROIC has decreased by 23% from the previous quarter and by 12% YoY
The return on assets has declined by 22% since the previous quarter but it has increased by 3.3% year-on-year
The company's return on equity fell by 21% QoQ but it rose by 3.3% YoY
Dividends
What is PMVP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PMVP.
Financial health
How did PMV Pharmaceuticals financials performed over time
The total liabilities is down by 43% year-on-year and by 41% since the previous quarter
The total assets has declined by 24% year-on-year and by 14% since the previous quarter
The debt is 99% smaller than the equity
The debt has dropped by 91% year-on-year and by 91% since the previous quarter
The company's debt to equity has shrunk by 86% QoQ and by 83% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.